Oslo, Norway, 15 November 2013 - Algeta ASA (OSE: ALGETA) announces today that Bayer has received marketing authorisation from the European Commission for Xofigo ® (radium Ra 223 dichloride) solution ...
Bayer announced today that new research findings on Xofigo ® (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical ...
Oslo, Norway, 20 September 2013 - Algeta ASA (OSE: ALGETA), announced today that Bayer has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for ...
In a study, select CRPC patients who benefited from initial radium‐223 therapy but later had bone progression were re-challenged with additional radium-223 injections and had no serious adverse ...
This week, the FDA approved radium-223 injection for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. It is the first FDA-approved alpha particle-emitting ...
The high risk of bone involvement in cases of hormone-refractory prostate cancer has previously been treated with bisphosphonates (which reduce the risk of skeletal events but do not extend survival) ...
Retrospective study to evaluate prostate cancer screening in a resident practice at a major teaching hospital. Background: Radium-223 chloride (Alpharadin) is a first-in-class targeted ...
The impact of molecular profiling guided targeted gold nanoparticles on radiosensitivity of metastatic salivary gland adenoid cystic carcinoma. Recombinant human adenovirus p53 injection enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results